85 studies found for:    topeka | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age
Conditions: Rubella;   Measles;   Mumps
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
22 Recruiting Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD
Conditions: COPD;   Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium Bromide;   Drug: Placebo
23 Available Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
24 Recruiting Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Drug: etoposide
25 Recruiting A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
Conditions: Diabetes Mellitus, Type 2;   Albuminuria
Interventions: Drug: Placebo;   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg
26 Recruiting Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients
Condition: Celiac Disease
Interventions: Drug: ALV003;   Drug: placebo
27 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
28 Recruiting Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: Nindetanib (BIBF 1120);   Drug: Placebo;   Drug: BSC
29 Recruiting S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
Conditions: Breast Cancer;   Musculoskeletal Complications;   Pain
Interventions: Drug: duloxetine hydrochloride;   Other: placebo
30 Recruiting Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention;   Other: counseling intervention;   Other: educational intervention;   Procedure: therapeutic dietary intervention
31 Recruiting Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Condition: Measles; Mumps; Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
32 Recruiting A Study of Lebrikizumab in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
Condition: Asthma
Interventions: Drug: lebrikizumab;   Drug: placebo
33 Recruiting A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MEDI4736;   Other: PLACEBO
34 Recruiting Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Condition: Atherosclerosis
Interventions: Drug: Canakinumab;   Drug: Placebo
35 Recruiting Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy;   Drug: docetaxel
36 Recruiting Randomized On-X Anticoagulation Trial
Condition: Heart Valve Disease
Interventions: Device: On-X valve using reduced anticoagulation;   Device: On-X Valve with Standard Coumadin Therapy
37 Recruiting Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
Conditions: Vaso-occlusive Crisis;   Sickle Cell Disease
Interventions: Drug: MST-188;   Drug: Saline
38 Recruiting Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castration-resistant Prostate Cancer
Interventions: Drug: Olaparib;   Drug: Placebo;   Drug: Abiraterone;   Drug: Prednisone or prednisolone
39 Recruiting Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: anti-B7H1 monoclonal antibody MEDI4736;   Drug: PI3 kinase inhibitor GDC-0032;   Drug: palbociclib isethionate;   Drug: FGFR inhibitor AZD4547;   Biological: rilotumumab;   Drug: docetaxel;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
40 Recruiting A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Placebo;   Drug: CP690,550;   Drug: CP-690,550

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years